Additionally, RAPID provides insulin‐mediated blood‐glucose control by a single oral dose of a clinically licensed drug, which advances the treatment options for diabetes, may improve patient convenience, and could make regular daily insulin injections a thing of the past. This evidence concerns the gene INS and diabetes mellitus.